Annals of Clinical Neurophysiology

The Korean Society of Clinical Neurophysiology (대한임상신경생리학회)
권호 표지
DOI QR코드

DOI QR Code

Neurolymphomatosis in patients with mantle cell lymphoma diagnosed by FDG PET-CT

  • Kim, Sooyoung (Department of Neurology, Chungnam National University Hospital) ;
  • An, Hakyeu (Department of Neurology, Chungnam National University Hospital) ;
  • Choi, Yoon Seok (Department of Hematology, Chungnam National University Hospital) ;
  • Park, Kee Hong (Department of Neurology, Chungnam National University Hospital) ;
  • Sohn, Eun Hee (Department of Neurology, Chungnam National University Hospital)
  • Received : 2019.11.07
  • Accepted : 2019.12.21
  • Published : 2020.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Neurolymphomatosis (NL) is characterized by the infiltration of malignant lymphoma cells into peripheral nerves, nerve roots, plexuses, or cranial nerves. This is a very rare complication of mantle-cell lymphoma. Diagnosing NL is made difficult by cerebrospinal fluid cytology and bone-marrow biopsy results often being negative. NL can appear as the only sign of recurrence in a patient with a previous diagnosis of lymphoma. Here we present two cases of NL in patients with mantle-cell lymphoma diagnosed by positron emission tomography with deoxy-fluoro-D-glucose integrated with computed tomography.

Keywords

References

  1. Davidson T, Kedmi M, Avigdor A, Komisar O, Chikman B, Lidar M, et al. FDG PET-CT evaluation in neurolymphomatosis: imaging characteristics and clinical outcomes. Leuk Lymphoma 2018;59:348-356. https://doi.org/10.1080/10428194.2017.1352096
  2. Pham M, Awad M. Lymphoma relapse presenting as neurolymphomatosis. Asian J Neurosurg 2016;11:73.
  3. DeVries AH, Howe BM, Spinner RJ, Broski SM. B-cell peripheral neurolymphomatosis: MRI and (18)F-FDG PET/CT imaging characteristics. Skeletal Radiol 2019;48:1043-1050. https://doi.org/10.1007/s00256-019-3145-3
  4. Vargas TC, Thomas RL, Erickson JC. Leptomeningeal enhancement in a patient with progressive cranial neuropathies and lumbosacral radiculopathies. JAMA Neurol 2016;73:345-346. https://doi.org/10.1001/jamaneurol.2015.3965
  5. Lin M, Kilanowska J, Taper J, Chu J. Neurolymphomatosis-diagnosis and assessment of treatment response by FDG PET-CT. Hematol Oncol 2008;26:43-45. https://doi.org/10.1002/hon.837
  6. Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutierrez G, et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008;19:135-141. https://doi.org/10.1093/annonc/mdm447
  7. Faivre G, Lagarde J, Choquet S, Maillart E, Lubetzki C. CNS involvement at diagnosis in mantle cell lymphoma with atypical MRI features. J Neurol 2014;261:1018-1020. https://doi.org/10.1007/s00415-014-7295-x
  8. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro Oncol 2003;5:104-115. https://doi.org/10.1215/S1522-8517-02-00017-0
  9. Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol 2010;12:212-215. https://doi.org/10.1093/neuonc/nop021
  10. Grisariu S, Avni B, Batchelor TT, van den Bent MJ, Bokstein F, Schiff D, et al. Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood 2010;115:5005-5011. https://doi.org/10.1182/blood-2009-12-258210